Olive Oil and Brain Health: 66% Lower Cognitive Impairment Risk in PREDIMED Trial

Extra virgin olive oil is one of the most studied foods in brain health research, and the evidence increasingly points to its polyphenol content -- including hydroxytyrosol, oleocanthal, and oleuropein -- as a key driver of cognitive protection. In the landmark PREDIMED trial, 522 older adults randomized to an EVOO-enriched Mediterranean diet for 6.5 years showed significantly better cognitive function and a 66% lower risk of mild cognitive impairment compared to a low-fat control group.

Why This Study Matters

The PREDIMED trial is one of the largest and most cited nutrition intervention studies ever conducted. It randomized over 7,400 people across Spain to test whether a Mediterranean diet -- rich in extra virgin olive oil or nuts -- could prevent cardiovascular events. The results, published in the New England Journal of Medicine, fundamentally changed how researchers and clinicians think about dietary fat.

But the cardiovascular findings weren't the only outcome. A subgroup of 522 participants from the PREDIMED-Navarra site underwent cognitive testing after 6.5 years of following their assigned diet. The question: does long-term EVOO consumption protect against cognitive decline in older adults at high vascular risk?

This is the first randomized controlled trial to demonstrate that an EVOO-enriched diet significantly improves cognitive function compared to a low-fat control. Prior evidence came exclusively from observational studies, which can show associations but not causation. PREDIMED-Navarra changed that. A companion PREDIMED cognitive substudy in Barcelona later extended these findings to a separate cohort.

How It Was Designed

Participants were drawn from the larger PREDIMED trial and randomized to one of three arms: a Mediterranean diet supplemented with one liter per week of extra virgin olive oil, a Mediterranean diet supplemented with 30 grams per day of mixed nuts, or a low-fat control diet. All participants were aged 55 to 80 at enrollment, at high cardiovascular risk, and received quarterly dietitian visits for the duration of the trial. After 6.5 years of intervention, 522 participants (mean age 74.6, 44.6% men) completed cognitive assessments.

Cognitive function was measured by two neurologists who were blinded to group assignment. They administered the Mini-Mental State Examination (MMSE), the standard screening tool for global cognitive function, and the Clock Drawing Test (CDT), which assesses visuospatial ability, executive function, and planning. A companion analysis on a subset of 268 participants included a more comprehensive neuropsychological battery covering memory, language, and executive function, and diagnosed mild cognitive impairment (MCI) according to International Working Group criteria.

Importantly, diet adherence was verified. By year six, the EVOO group scored 10.8 out of 14 on the Mediterranean diet adherence questionnaire, compared to just 6.3 for controls (p < 0.001).

What They Found

After adjusting for 13 confounders -- including age, education, ApoE genotype, diabetes, and physical activity -- the EVOO group significantly outperformed the control group on both cognitive tests:

Outcome	EVOO vs. Control	95% CI	p-value	What It Measures
MMSE Score	+0.62 points	+0.18 to +1.05	0.005	Global cognitive function
Clock Drawing Test	+0.51 points	+0.20 to +0.82	0.001	Visuospatial ability, executive function
Nuts vs. Control (MMSE)	+0.57 points	+0.11 to +1.03	0.015	Global cognitive function
Nuts vs. Control (CDT)	+0.33 points	+0.003 to +0.67	0.048	Visuospatial ability, executive function

Positive values indicate better performance vs. the low-fat control group. All differences are adjusted for 13 covariates and are statistically significant.

The companion analysis on the subset with full neuropsychological testing found that the EVOO group also performed significantly better on visual memory, verbal fluency, and working memory tasks. Most critically, the EVOO group had a 66% lower risk of developing mild cognitive impairment:

Group	MCI Cases	Odds Ratio vs. Control	95% CI	p-value
EVOO	7 of 90 (7.8%)	0.34	0.12 - 0.97	0.024
Nuts	10 of 85 (11.8%)	0.56	0.22 - 1.43	0.171
Control	17 of 88 (19.3%)	Reference	--	--

MCI = mild cognitive impairment. Odds ratios are adjusted for sex, age, education, ApoE genotype, family history, smoking, physical activity, BMI, hypertension, dyslipidemia, diabetes, alcohol, and energy intake.

Reading the Results

The EVOO group consistently outperformed both the nuts group and the control group across cognitive domains. On global cognitive screening (MMSE and CDT), the differences were statistically significant and clinically meaningful for a population in their mid-70s, where even small point differences can indicate the boundary between normal cognition and early decline. The EVOO group scored 0.62 points higher on the MMSE and 0.51 points higher on the CDT than controls -- differences that held up after adjusting for 13 potential confounders including genetic risk (ApoE4 status).

The MCI finding is the most striking result. Only 7.8% of the EVOO group developed mild cognitive impairment over 6.5 years, compared to 19.3% of the low-fat control group. That's a 66% reduction in risk after full adjustment. The nuts group fell in between (11.8%) but the difference from control was not statistically significant. This pattern -- where EVOO outperforms both nuts and control on cognitive outcomes -- suggests that something specific to olive oil, beyond its fat profile, is contributing to the cognitive benefit. The polyphenol content of extra virgin olive oil, including hydroxytyrosol, oleuropein, and oleocanthal, is the most likely explanation.

The extended neuropsychological battery revealed domain-specific patterns. The EVOO group showed the largest advantages in visual memory (Rey-Osterrieth Complex Figure, both immediate and delayed recall), verbal fluency (FAS test), and working memory (digit span forward). These are the cognitive domains most sensitive to early neurodegenerative changes and most dependent on intact prefrontal and temporal lobe function.

What Didn't Change

Dementia incidence was too low to analyze -- only 5 cases across all three groups over 6.5 years. No significant interactions were found between diet assignment and sex, education level, or ApoE4 carrier status, meaning the cognitive benefits were not limited to a specific genetic or demographic subgroup. The results also did not change after controlling for incident depression.

Broader Context

PREDIMED is the gold standard in Mediterranean diet research. The primary cardiovascular results, published in the New England Journal of Medicine, showed a 30% reduction in cardiovascular events with the Mediterranean diet. The cognitive substudy published in the Journal of Neurology, Neurosurgery & Psychiatry extends those findings to the brain.

The European Food Safety Authority (EFSA) has authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage. The connection to cognition is increasingly clear: the same oxidative and inflammatory processes that damage arteries also damage neurons. A compound that protects vascular endothelium is also, in principle, protecting the brain's vascular supply.

What makes PREDIMED-Navarra unique in the cognitive literature: it's a 6.5-year randomized intervention, not a cross-sectional snapshot. It controlled for genetic risk. It blinded the assessors. And it showed that the EVOO arm -- not the nut arm -- drove the strongest cognitive effects, pointing toward olive-specific compounds rather than generic healthy fat intake.

Related Research

Continue exploring olive oil and polyphenol science:

• PREDIMED Republished: Mediterranean Diet + EVOO Cut Major CV Events by 30%
• Olive Oil Linked to 28% Lower Dementia Death in 92,383 Adults
• Hydroxytyrosol Improved Complex Attention in Adults Aged 51 to 82

Source: View the original study on PubMed

Olivea's Dosage

Participants in the EVOO arm received one liter per week of extra virgin olive oil for cooking and daily use. Olivea's high-phenolic EVOOs are independently tested for polyphenol content, and each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving -- confirmed at 23.5 mg per capsule on our most recent third-party certificate of analysis.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.